Please provide your email address to receive an email when new articles are posted on . According to a release from Neurocrine Biosciences Inc., the selective vesicular monoamine transporter 2 ...

Credit: Neurocrine Biosciences. Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period. The Food and Drug ...

Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

SAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body regions with ...

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT ®-HD2 study of INGREZZA ® (valbenazine) ...

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with ...

In a study on treatments and outcomes in patients with Sydenham chorea (SC), corticosteroids were associated with faster resolution, while antibiotics, corticosteroids, and sodium valproate were ...

SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (valbenazine) capsules ...